このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Bloomage BioTechnology マネジメント

マネジメント基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Yan Zhao

最高経営責任者

CN¥2.0m

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	0.02%
経営陣の平均在職期間	4.6yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

更新なし

Recent updates

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Jun 02

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

May 06

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

May 01

CEO（最高経営責任者

Yan Zhao (58 yo)

no data

在職期間

CN¥2,024,900

報酬

Ms. Yan Zhao serves as the Chairwoman at Pando Group Limited. She is also the majority shareholder in and serves as Chairman and Executive Director of Bloomage BioTechnology Corporation Limited and serves...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yan Zhao	Chairman & GM	no data	CN¥2.02m	0.024% CN¥ 6.5m
Jiajun Guo	Deputy GM & Director	no data	CN¥925.30k	0.012% CN¥ 3.1m
Xueping Guo	Deputy GM of Core Technician & Director	no data	CN¥946.70k	0.017% CN¥ 4.6m
Yizheng Li	Deputy GM	no data	CN¥1.70m	データなし
Aihua Liu	Deputy General Manager	no data	CN¥1.82m	0.015% CN¥ 4.0m
Guixin Xu	Deputy General Manager	5.3yrs	CN¥734.90k	0.0092% CN¥ 2.5m
Gao Yi	Deputy General Manager	3.4yrs	CN¥1.00m	0.0026% CN¥ 707.7k
Luan Yizheng	Deputy General Manager	4.6yrs	CN¥1.01m	0.012% CN¥ 3.1m

4.6yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: 688363の経営陣は経験豊富であると考えられます ( 4.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yan Zhao	Chairman & GM	no data	CN¥2.02m	0.024% CN¥ 6.5m
Jiajun Guo	Deputy GM & Director	no data	CN¥925.30k	0.012% CN¥ 3.1m
Xueping Guo	Deputy GM of Core Technician & Director	no data	CN¥946.70k	0.017% CN¥ 4.6m
Yizheng Li	Deputy GM	no data	CN¥1.70m	データなし
Yingqian Wang	Independent Director	5.3yrs	CN¥150.00k	データなし
Fuguo Cao	Independent Director	5.3yrs	CN¥150.00k	データなし
Changmei Zhao	Supervisor	4.1yrs	データなし	データなし
Dongni Li	Employee Representative Supervisor	4.1yrs	データなし	データなし
Jing Yu	Chairman of the Supervisory Board	no data	データなし	データなし
Songyan Zou	Director	2.3yrs	CN¥626.90k	0.0019% CN¥ 505.9k
Yuan Fan	Director	2.3yrs	CN¥862.90k	0.0038% CN¥ 1.0m
Guanting Chen	Independent Director	2.3yrs	CN¥150.00k	データなし

4.1yrs

平均在職期間

54.5yo

平均年齢

経験豊富なボード: 688363の取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

Bloomage BioTechnology マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Recent updates

Bloomage BioTechnology Corporation Limited to Report First Half, 2024 Results on Aug 24, 2024

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

Price target decreased by 9.9% to CN¥75.39

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 9.9% to CN¥83.72

Bloomage BioTechnology Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 8.6% to CN¥99.40

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 18%

Consensus revenue estimates fall by 12%

Second quarter 2023 earnings: EPS misses analyst expectations

Bloomage BioTechnology Corporation Limited (SHSE:688363) announces an Equity Buyback for CNY 300 million worth of its shares.

Bloomage BioTechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 7.9% to CN¥120

Price target decreased by 8.2% to CN¥126

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥150

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to CN¥168

Second quarter 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥153

Price target decreased to CN¥181

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥196

Price target decreased to CN¥239

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.35 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥245

First quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.23 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.35 (vs CN¥1.34 in FY 2019)

New 90-day low: CN¥134

New 90-day high: CN¥208

New 90-day high: CN¥192

Price target raised to CN¥175

New 90-day high: CN¥150

Bloomage BioTechnology Corporation Limited to Report Q3, 2020 Results on Oct 30, 2020

Bloomage BioTechnology Corporation Limited (SHSE:688363) completed the acquisition of Dongying Fusite Biological Engineering Co., Ltd. from Eastar Holdings Group CO.,LTD and Zhang Zhenwu.

New 90-day low - CN¥119

First half earnings released

Bloomage BioTechnology Corporation Limited to Report First Half, 2020 Results on Aug 26, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44